Longitudinal Protection Following Natural SARS-CoV-2 Infection and Early Vaccine&amp;nbsp;Responses: Insights from a Cohort of Community Based Dental Health Care Professionals

Shields, Adrian; Faustini, Sian; Kristunas, Caroline; Cook, Alex M; Backhouse, Claire; Dunbar, Lynsey; Ebanks, Daniel; Emmanuel, Beena; Crouch, Eddie; Kroeger, Annika Therese; Hirschfeld, Josefine; Sharma, Praveen; Jafery, Razza; S, Nowak; Gee, S.; Drayson, Mark T.; Richter, Alex; Thränhardt, Dietrich; Chapple, Iain L. C.

doi:10.2139/ssrn.3785996

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis

Chen

Zhu

Liu

et al. 2022

Emerging Microbes & Infections

View full text Add to dashboard Cite

The specific antibodies induced by SARS-CoV-2 infection may provide protection against a subsequent infection. However, the efficacy and duration of protection provided by naturally acquired immunity against subsequent SARS-CoV-2 infection remain controversial. We systematically searched for the literature describing COVID-19 reinfection published before 07 February 2022. The outcomes were the pooled incidence rate ratio (IRR) for estimating the risk of subsequent infection. The Newcastle–Ottawa Scale (NOS) was used to assess the quality of the included studies. Statistical analyses were conducted using the R programming language 4.0.2. We identified 19 eligible studies including more than 3.5 million individuals without the history of COVID-19 vaccination. The efficacy of naturally acquired antibodies against reinfection was estimated at 84% (pooled IRR = 0.16, 95% CI: 0.14-0.18), with higher efficacy against symptomatic COVID-19 cases (pooled IRR = 0.09, 95% CI = 0.07-0.12) than asymptomatic infection (pooled IRR = 0.28, 95% CI = 0.14-0.54). In the subgroup analyses, the pooled IRRs of COVID-19 infection in health care workers (HCWs) and the general population were 0.22 (95% CI = 0.16-0.31) and 0.14 (95% CI = 0.12-0.17), respectively, with a significant difference ( P = 0.02), and those in older (over 60 years) and younger (under 60 years) populations were 0.26 (95% CI = 0.15–0.48) and 0.16 (95% CI = 0.14-0.19), respectively. The risk of subsequent infection in the seropositive population appeared to increase slowly over time. In conclusion, naturally acquired antibodies against SARS-CoV-2 can significantly reduce the risk of subsequent infection, with a protection efficacy of 84%. Registration number: CRD42021286222

show abstract

The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis

Chen

Zhu

Liu

et al. 2022

Emerging Microbes & Infections

View full text Add to dashboard Cite

show abstract

Rapid semi-quantitative point of care diagnostic test for post vaccination antibody monitoring

Moeller

Engsig

Bade³

et al. 2021

Preprint

View full text Add to dashboard Cite

Introduction: Point-of-care (POC) quantification of the antibody responses against the SARS-CoV-2 Spike protein can enable decentralized monitoring of immune responses after infection or vaccination. We evaluated a novel POC microfluidic cartridge-based device (ViroTrack Sero COVID-19 Total Ab) for quantitative detection of total antibodies against SARS-CoV-2 Spike trimeric spike protein and compared to standard laboratory chemiluminescence (CLIA) based tests. Methods: Capillary- and venous blood samples were collected from 101 individuals employed at Copenhagen University Hospital, Denmark. Antibody responses were measured on capillary-, venous whole blood, plasma and diluted plasma samples directly on the POC instrument. POC results were available within seven minutes on the microfluidic cartridge reader. Plasma samples were analysed on the DiaSorin LIAISON XL CLIA Analyzer using LIAISON SARS-CoV-2 IgM, LIAISON SARS-CoV-2 S1/S2 IgG and LIAISON SARS-CoV-2 TrimericS IgG assays. The data from the CLIA platform was used as a reference. Results: The Spearman rank correlation coefficient between ViroTrack Sero COVID-19 Total Ab and LIAISON SARS-CoV-2 S1/S2 IgG and LIAISON SARS-CoV-2 TrimericS IgG assays is found to be 0.86 and 0.90 respectively. ViroTrack Sero COVID-19 Total Ab furthermore showed high correlation (>0.86) among the different sample matrixes. The agreement for determination of samples >200 BAU/mL on POC and CLIA methods is estimated to be around 90%. Conclusion: ViroTrack Sero Covid Total Ab is a very rapid and simple-to-use POC test with high sensitivity and high correlation of the numerical results expressed in BAU/mL when compared to a commercial CLIA assay.

show abstract

Longitudinal Protection Following Natural SARS-CoV-2 Infection and Early Vaccine Responses: Insights from a Cohort of Community Based Dental Health Care Professionals

Cited by 2 publications

References 0 publications

The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis

The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis

Rapid semi-quantitative point of care diagnostic test for post vaccination antibody monitoring

Contact Info

Product

Resources

About